Drugs / SY-008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04345120 | Jun 2020 → Dec 2021 | type 2 diabetes mellitus | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03462589 | Aug → Dec 2018 | diabetes mellitus | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03462589 ↗ |
| Route | Oral | “taken orally” NCT03462589 ↗ |